Bio-Path Stock Analysis


USD 3.18  0.30  8.62%   

The current drop in stock price could raise concerns from stockholders as the firm is trading at a share price of 3.18 on 118,000 in volume. The company directors and management have failed to build on market volatilities in August. However, diversifying your overall positions with Bio-Path Holdings may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.43. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Bio-Path Holdings partners.
Continue to Trending Equities.
The Bio-Path Holdings stock analysis report makes it easy to digest most publicly released information about Bio-Path Holdings and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bio-Path Stock analysis module also helps to analyze the Bio-Path Holdings price relationship with some important fundamental indicators such as market cap and management efficiency.

Bio-Path Stock Analysis Notes

The company has price-to-book (P/B) ratio of 1.09. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio-Path Holdings recorded a loss per share of 2.83. The entity had not issued any dividends in recent years. The firm had a split on the 18th of January 2019. Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. For more info on Bio-Path Holdings please contact Peter Nielsen at 832 742-1357 or go to

Bio-Path Holdings Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bio-Path Holdings' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bio-Path Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bio-Path Holdings generated a negative expected return over the last 90 days
Bio-Path Holdings has high historical volatility and very poor performance
The company reported the previous year's revenue of 37 K. Net Loss for the year was (11.35 M) with profit before overhead, payroll, taxes, and interest of 37 K.
Bio-Path Holdings currently holds about 21.25 M in cash with (10.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97.
Latest headline from Chamath Palihapitiya Is Giving Up on IPOF, IPOD Stocks - InvestorPlace

Bio-Path Holdings Upcoming and Recent Events

Earnings reports are used by Bio-Path Holdings to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio-Path Holdings previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of March 2022
Next Financial Report13th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End9th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Bio-Path Holdings SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bio-Path Holdings prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bio-Path Holdings investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bio-Path Holdings specific information freely available to individual and institutional investors to make a timely investment decision.
6th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure
16th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
17th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
12th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure
6th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
11th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
8th of March 2022
Financial Statements and Exhibits. Regulation FD Disclosure
25th of February 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Bio-Path Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Bio-Path Holdings is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio-Path Holdings backward and forwards among themselves. Bio-Path Holdings' institutional investor refers to the entity that pools money to purchase Bio-Path Holdings' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares221.5 K857 K
Geode Capital Management LlcCommon Shares67.5 K261 K
Blackrock IncCommon Shares48.5 K188 K
Renaissance Technologies LlcCommon Shares18 K70 K
Northern Trust CorpCommon Shares17.3 K67 K
State Street CorpCommon Shares13 K50 K
Dimensional Fund Advisors LpCommon Shares13 K50 K
Note, although Bio-Path Holdings' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bio-Path Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 25.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio-Path Holdings's market, we take the total number of its shares issued and multiply it by Bio-Path Holdings's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (24.82) % which means that it has lost $24.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (42.29) %, meaning that it created substantial loss on money invested by shareholders. Bio-Path Holdings management efficiency ratios could be used to measure how well bio-path holdings manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 24th of September, Bio-Path Holdings shows the risk adjusted performance of (0.08), and Mean Deviation of 2.38. Bio-Path Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Bio-Path Holdings, which can be compared to its rivals. Please confirm Bio-Path Holdings coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bio-Path Holdings is priced correctly, providing market reflects its regular price of 3.18 per share. Given that Bio-Path Holdings has jensen alpha of (0.22), we suggest you to validate Bio-Path Holdings's prevailing market performance to make sure the company can sustain itself at a future point.

Bio-Path Holdings Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Bio-Path Holdings price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Bio-Path Holdings Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio-Path Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio-Path Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio-Path Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bio-Path Holdings Predictive Daily Indicators

Bio-Path Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bio-Path Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bio-Path Holdings Forecast Models

Bio-Path Holdings time-series forecasting models is one of many Bio-Path Holdings' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bio-Path Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Bio-Path Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bio-Path Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bio-Path shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Bio-Path Holdings. By using and applying Bio-Path Stock analysis, traders can create a robust methodology for identifying Bio-Path entry and exit points for their positions.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Current Bio-Path Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bio-Path analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bio-Path analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.5Strong Buy2Odds
Bio-Path Holdings current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bio-Path analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bio-Path stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bio-Path Holdings, talking to its executives and customers, or listening to Bio-Path conference calls.
Bio-Path Analyst Advice Details

Bio-Path Stock Analysis Indicators

Bio-Path Holdings stock analysis indicators help investors evaluate how Bio-Path Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bio-Path Holdings shares will generate the highest return on investment. By understating and applying Bio-Path Holdings stock analysis, traders can identify Bio-Path Holdings position entry and exit signals to maximize returns.
Quick Ratio13.55
Fifty Two Week Low2.6800
Shares Short Prior Month88.94k
Average Daily Volume Last 10 Day12.16k
Average Daily Volume In Three Month28.42k
Shares Percent Shares Out0.74%
Short Percent Of Float0.74%
Forward Price Earnings-2.27
Float Shares7.13M
Fifty Two Week High5.4800
Enterprise Value To Ebitda-0.40
Fifty Day Average3.8566
Two Hundred Day Average3.6958
Continue to Trending Equities. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for analysis

When running Bio-Path Holdings price analysis, check to measure Bio-Path Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio-Path Holdings is operating at the current time. Most of Bio-Path Holdings' value examination focuses on studying past and present price action to predict the probability of Bio-Path Holdings' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bio-Path Holdings' price. Additionally, you may evaluate how the addition of Bio-Path Holdings to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Bio-Path Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio-Path Holdings. If investors know Bio-Path will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio-Path Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bio-Path Holdings is measured differently than its book value, which is the value of Bio-Path that is recorded on the company's balance sheet. Investors also form their own opinion of Bio-Path Holdings' value that differs from its market value or its book value, called intrinsic value, which is Bio-Path Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio-Path Holdings' market value can be influenced by many factors that don't directly affect Bio-Path Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio-Path Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine Bio-Path Holdings value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio-Path Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.